当前位置: 首页 >> 检索结果
共有 19838 条符合本次的查询结果, 用时 2.927094 秒

801. Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response.

作者: Yves Renaudineau.;Emmanuel Treiner.;Magali Colombat.;Gregory Pugnet.;Laurent Sailler.;Antoine Huart.;Stanislas Faguer.;Julie Belliere.
来源: Rheumatology (Oxford). 2025年64卷12期6319-6327页
This study aims to assess urinary soluble CD163 normalized to creatinuria (usCD163/Cre) alongside conventional biomarkers as indicators of renal activity and therapeutic response in LN.

802. Further progression in patients with systemic sclerosis-associated interstitial lung disease - Authors' reply.

作者: Anna-Maria Hoffmann-Vold.;Oliver Distler.; .
来源: Lancet Rheumatol. 2025年7卷10期e670-e671页

803. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.

作者: Melanie Hagen.;Fabian Müller.;Andreas Wirsching.;Soraya Kharboutli.;Silvia Spoerl.;Christina Düsing.;Tobias Krickau.;Markus Metzler.;Simon Völkl.;Michael Aigner.;Sascha Kretschmann.;Ingrid Vasova.;Marc Saake.;Stefan Schliep.;Torsten Kubacki.;Nicolas Hunzelmann.;Laura Bucci.;Jule Taubmann.;Christina Bergmann.;Andrea-Hermina Györfi.;Sascha Dietrich.;Jörg H W Distler.;Ricardo Grieshaber-Bouyer.;Andreas Mackensen.;Georg Schett.
来源: Lancet Rheumatol. 2025年7卷10期e667-e669页

804. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus.

作者: Chunmei Wu.;Ran Wang.;Yan Ye.;Shuang Ye.;Qiong Fu.
来源: Lancet Rheumatol. 2025年7卷10期e667页

805. Aspirin desensitisation in pregnant individuals with autoimmune disease.

作者: Pradip Dashraath.;Samantha Neubronner.;Soon Leong Yong.;Roziah Husin.;Amelia Santosa.;Shiao-Yng Chan.;Sen Hee Tay.
来源: Lancet Rheumatol. 2025年7卷10期e665-e666页

806. Further progression in patients with systemic sclerosis-associated interstitial lung disease.

作者: Anaïs Roeser.;Yurdagül Uzunhan.
来源: Lancet Rheumatol. 2025年7卷10期e669-e670页

807. Personalised gait retraining for medial compartment knee osteoarthritis: a randomised controlled trial.

作者: Scott D Uhlrich.;Valentina Mazzoli.;Amy Silder.;Andrea K Finlay.;Feliks Kogan.;Garry E Gold.;Scott L Delp.;Gary S Beaupre.;Julie A Kolesar.
来源: Lancet Rheumatol. 2025年7卷10期e708-e718页
Retraining individuals with medial compartment knee osteoarthritis to walk with a patient-specific change in their foot angle (ie, toe-in or toe-out angle) can reduce excessive joint loading related to disease progression. This study investigated the clinical, biomechanical, and structural efficacy of personalised foot progression angle modifications compared with sham treatment in patients with mild-to-moderate medial compartment knee osteoarthritis.

808. Looking to the new horizon in rheumatology research.

作者: Elizabeth C Rosser.;Lucy R Wedderburn.
来源: Nat Rev Rheumatol. 2025年21卷11期644-645页

809. Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: a multicentre retrospective study.

作者: Arsène Mekinian.;Sarah Meneses.;Lucie Biard.;Lorenzo Dagna.;Pavel Novikov.;Carlo Salvarani.;Olivier Espitia.;Savino Sciscia.;Martin Michaud.;Marc Lambert.;José Hernández-Rodríguez.;Nicolas Schleinitz.;Abid Awisat.;Xavier Puéchal.;Achille Aouba.;Heloise Munoz Pons.;Ilya Smitienko.;Jean Baptiste Gaultier.;Le Mouel Edwige.;Ygal Benhamou.;Antoinette Perlat.;Patrick Jego.;Tiphaine Goulenok.;Karim Sacre.;Bertrand Lioger.;Nolan Hassold.;Jonathan Broner.;Virginie Dufrost.;Thomas Sene.;Julie Seguier.;Francois Maurier.;Sabine Berthier.;Alexandre Belot.;Faten Frikha.;Guillaume Denis.;Alexandra Audemard-Verger.;Isabelle Koné-Paut.;Sebastien Humbert.;Pascal Woaye-Hune.;Alessandro Tomelleri.;Elena Baldissera.;Masataka Kuwana.;Alberto Lo Gullo.;Vahan Mukuchyan.;Azeddine Dellal.;Francis Gaches.;Pierre Zeminsky.;Chiara Marvisi.;Moya Alvarado.;Luigi Boiardi.;Francesco Muratore.;Mathieu Vautier.;Corrado Campochiaro.;Sergey Moiseev.;Matheus Vieira.;Patrice Cacoub.;Olivier Fain.;David Saadoun.; .
来源: Rheumatology (Oxford). 2025年64卷12期6192-6200页
In this large multicentre study, we aimed to compare the effectiveness of intravenous infliximab (IFX) vs subcutaneous adalimumab (ADA) in patients with Takayasu arteritis (TAK).

810. The four Ds-the four things that matter most to ensure rheumatic disease control in pregnancy and beyond.

作者: Bethan Goulden.;Ian Giles.
来源: Rheumatology (Oxford). 2025年64卷12期6017-6018页

811. A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC score.

作者: Cosimo Bruni.;Lorenzo Tofani.;Håvard Fretheim.;Sophie I E Liem.;Arthiha Velauthapillai.;Hilde Bjørkekjær.;Imon Barua.;Ilaria Galetti.;Alexandru Garaiman.;Mike O Becker.;Anna-Maria Hoffmann-Vold.;Jeska de Vries-Bouwstra.;Madelon C Vonk.;Jörg H W Distler.;Marco Matucci-Cerinic.;Oliver Distler.
来源: Rheumatology (Oxford). 2025年64卷12期6285-6293页
As a screening tool for the presence of systemic sclerosis-associated interstitial lung disease (SSc-ILD) on high-resolution computed tomography (HRCT) is missing, we aimed to develop the ILD-RISC score, a risk algorithm to guide physicians in ordering HRCTs, with specific focus on follow-up visits.

812. Identification of a novel TGFB1 variant in a patient with Camurati-Engelmann disease responsive to alendronate.

作者: Neelam Hassan.;Celia L Gregson.;Michael Oldridge.;Tracy Lester.;Emma L Duncan.;Jonathan H Tobias.
来源: Rheumatology (Oxford). 2025年64卷12期6427-6429页

813. How early is early for JIA? Insights from the infantile-onset juvenile idiopathic arthritis patients of the PERA research group cohort.

作者: Kubra Ozturk.;Tuncay Aydin.;Gulcan Ozomay Baykal.;Esra Baglan.;Hulya Kose.;Hakan Kisaoglu.;Deniz Gezgin Yildirim.;Fatma Gul Demirkan.;Gulcin Otar Yener.;Mustafa Çakan.;Belde Kasap Demir.;Hatice Adiguzel Dundar.;Gulsah Kilbas.;Hafize Emine Sonmez.;Serkan Turkucar.;Balahan Bora.;Selcuk Yuksel.;Nuray Aktay Ayaz.;Sevcan Bakkaloglu.;Mukaddes Kalyoncu.;Sara Sebnem Kilic.;Semanur Ozdel.;Betul Sozeri.;Erbil Unsal.
来源: Rheumatology (Oxford). 2025年64卷12期6278-6284页
Juvenile idiopathic arthritis (JIA) is the most common chronic childhood arthritis, with distinct categories based on pathophysiology and clinical manifestations. The age of onset varies by category but is reported to be approximately six years. This study aimed to evaluate the clinical, laboratory and outcome characteristics of patients with infantile-onset JIA.

814. High ischemic deficit in computed tomography perfusion is a risk factor for cerebral vascular ischemic events in Takayasu arteritis: a prospective observational study.

作者: Rongyi Chen.;Ying Sun.;Ying Liu.;Jing Ding.;Lindi Jiang.
来源: BMC Rheumatol. 2025年9卷1期100页
Patients suffering from Takayasu arteritis (TA) with stenosis or occlusion of supra-aortic trunks carry a high risk of cerebral vascular ischemic events (CVIEs). We explored the relationship between cerebral blood perfusion and CVIEs in TA.

815. Patient characteristics and adverse effects of allogeneic blood transfusion following lower extremity joint replacement in rheumatoid arthritis: a nationwide inpatient sample database study.

作者: Wenyan Geng.;Lulu Ye.;Xuegao Yu.;Qinfeng Yang.;Linlin Wang.;Xiaodan Li.;Qing Xiao.;Jian Wang.
来源: BMC Rheumatol. 2025年9卷1期101页
Allogeneic blood transfusion is a common therapeutic intervention for patients with rheumatoid arthritis (RA) undergoing lower extremity joint replacement (LEJR). Despite the potential for adverse outcomes associated with blood transfusion, the risks related to this procedure in RA patients remain underexplored, particularly within the framework of a large-scale national dataset.

816. Successful treatment of refractory chilblain lupus erythematosus with bosentan.

作者: Shannon Gunawardana.;Alexander J Clarke.;Antonia Lloyd-Lavery.;Shirish Dubey.
来源: Rheumatology (Oxford). 2025年64卷12期6430-6431页

817. Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence.

作者: Andy Nolan.;Daniel M Foulkes.;Emma E Fairweather.;Michele Fresneda Alarcon.;Christina Linford.;Andrew Sellin.;Zoe McLaren.;Patrick A Eyers.;Helen L Wright.
来源: Rheumatology (Oxford). 2025年64卷12期6409-6414页
Activation of neutrophils and release of neutrophil extracellular traps (NETs), proteases and reactive oxygen species (ROS) is pathogenic in immune-mediated inflammatory diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), driving inflammation and damaging host tissues. The aim of this research was to identify small molecule inhibitors of NET production using a highly curated panel of narrow-spectrum small molecule kinase inhibitors termed the kinase chemogenomic set (KCGS).

818. Anxiety symptoms and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a cross-sectional study.

作者: Sabrina Provencher.;Marie-Eve Carrier.;Gabrielle Virgili-Gervais.;Meira Golberg.;Richard S Henry.;Linda Kwakkenbos.;Catherine Fortuné.;Amy Gietzen.;Karen Gottesman.;Geneviève Guillot.;Amanda Lawrie-Jones.;Maureen Sauvé.;Susan J Bartlett.;Laura K Hummers.;Vanessa Malcarne.;Maureen D Mayes.;Michelle Richard.;James Stempel.;Robyn K Wojeck.;Luc Mouthon.;Andrea Benedetti.;Brett D Thombs.; .
来源: Rheumatology (Oxford). 2025年64卷12期6268-6277页
We (1) compared anxiety symptom levels in a multinational SSc cohort to a general population normative sample and (2) evaluated sociodemographic, lifestyle and SSc disease factors associated with symptoms.

819. Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain.

作者: Vicky Batchelor.;Thomas A Perry.;M Zameel Cader.;Tonia L Vincent.
来源: Nat Rev Rheumatol. 2025年21卷9期526-545页
Pain is the primary complaint in individuals with osteoarthritis (OA) and changes as the disease progresses. Anatomical changes in several joint structures potentially contribute to pain, including the increased innervation of the periosteum, synovium and subchondral bone, and the pathological innervation of articular cartilage, which is aneural under physiological conditions. Research has focused on molecules that sensitize afferent neurons, such as neuropeptides, neurotrophins, pro-inflammatory cytokines and ion channels. The neurotrophin nerve growth factor (NGF) is the best validated target in OA pain, with proven analgesic effects in preclinical and clinical studies, although the development of NGF-targeted therapeutics has been hampered by serious side effects. One relatively neglected area of research is the contribution to OA pain of the molecular pathways that mediate remodelling of nerves in disease. Remodelling requires coordination between the nerve and the associated vasculature, along with signals that are received from the surrounding parenchyma. Key cell guidance molecules, including angiogenic factors, ephrins, semaphorins and SLIT proteins are involved in nerve growth during development, and their expression is increased in osteoarthritic joints.

820. Tenosynovitis in rheumatoid arthritis: the often-forgotten friend (or foe).

作者: Ilfita Sahbudin.;Nicola Gullick.
来源: Rheumatology (Oxford). 2026年65卷1期
共有 19838 条符合本次的查询结果, 用时 2.927094 秒